TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05773365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PENG block with or without local anaesthetic infiltration
Description: As mentioned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PENG block with or without local anaesthetic infiltration
Description: As mentioned.
Study: NCT05870787

Intervention type: DIAGNOSTIC_TEST
Intervention: Swede score colposcopy
Description: New colposcopy method: with application of acetic acid, supplemented with a systematic scoringsystem (Swede score) including Lugols iodine, and collection of cervical biopsies.
Study: NCT05886777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination [RSVpreF+BNTb162b2]
Description: Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination [RSVpreF+BNTb162b2]
Description: Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Bivalent BNT162b2 given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Bivalent BNT162b2 given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omi BA.4/BA.5)
Description: Bivalent BNT162b2 given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVpreF
Description: RSVpreF given as an intramuscular injection
Study: NCT06400355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: in which mannitol will be given in doses of 0.5 gm/kg 30 minutes before the end of the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
Study: NCT06515054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wall squat
Description: self-learnt wall squat exercise to be conducted for totally 24 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: passive stretching
Description: time-matched passive stretching exercise to be conducted for totally 24 weeks
Study: NCT04807439

Intervention type: DEVICE
Intervention: SYNERGY XLV (Megatron) Coronary Stent System
Description: The SYNERGY MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries \>3.50 mm to \<5.00 mm in diameter in lesions \<28 mm in length.
Study: NCT04926805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP with Mask A
Description: CPAP mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with Mask B
Description: CPAP mask
Study: NCT06427161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT application
Description: The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLLT application
Description: The LLLT group received the laser application at 8 points, once a week, over a 2-month period, totaling 8 sessions. Each point was stimulated for 8 seconds in the soft palate, uvula, pharyngeal walls, palatine tonsils, and on the tongue base. LLLT protocol: Diode laser 810nm in continuous contact mode was used, and the radiant energy was 2J (250uw X 8 sec) for each point. Total energy was 16J (2J X 8 points) for each session.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dextrose injection
Description: 25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dextrose injection
Description: 25% dextrose was injected in the same 8 points; 1/2 ml for each point, total 4ml for each session. The injection was done weekly, up to 4 sessions.
Study: NCT05442021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neubie Direct Current Electrical Stimulation Device
Description: Direct Current Electrical Stimulation Device that uses electrodes non-invasively on the skin to stimulate muscle fibers.

Intervention type: DEVICE
Group type: OTHER
Intervention: TENS
Description: Transcutaneous Electrical Nerve Stimulation device - uses alternating current delivered through electrodes on the skin.
Study: NCT05886777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSVpreF given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSVpreF given as an intramuscular injection
Study: NCT05417113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine 0.25% in ESP blocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine 0.25% in ESP blocks
Study: NCT05804903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
Description: Implantation of the ALLEGRA Plus Transcatheter Heart Valve in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
Study: NCT05370326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Opioid Stewardship Program
Description: The goal of the enhanced opioid stewardship intervention is to manage chronic pain while reducing risk of inappropriate/risky opioid use and preventing harms of opioid use.
Study: NCT05886777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Licensed QIV given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QIV
Description: Licensed QIV given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIV
Description: Licensed QIV given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Placebo
Description: Normal saline (0.9% sodium chloride solution for injection)
Study: NCT06349954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-session ERCP
Description: directly endoscopic stone extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-session ERCP
Description: early endoscopic drainage followed by endoscopic stone extraction
Study: NCT05405712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone App
Description: App-based peer support program, used in conjunction with standard outpatient treatment
Study: NCT05053828

Intervention type: DRUG
Intervention: Antiplatelet Drug
Description: Antiplatelet drugs and agents
Study: NCT06061614

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: NGGT002
Study: NCT05053828

Intervention type: DRUG
Intervention: Antiplatelet Drug
Description: Antiplatelet drugs and agents

Intervention type: DRUG
Intervention: Antiplatelet Drug
Description: Antiplatelet drugs and agents
Study: NCT05296278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-323 combined with bevacizumab plus Platinum
Description: IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-323 combined with bevacizumab plus Platinum
Description: IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
Study: NCT04462146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Self Applied Treatment Program
Description: It is a self-applied treatment for PGD through the web psicologíaytecnología.labpsitec.es. There are 8 treatment modules. Each module lasts approximately 60 minutes. It contains written information, videos, audios, photos and interactive questionnaires. The total duration of treatment is up to 8-10 weeks. A weekly support call will be made (maximum 10 minutes) to answer questions and reinforce and motivate the patient. No additional clinical content or counselling will be provided. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Videoconference treatment with a therapist
Description: It is a treatment for PGD applied by a therapist composed of 8-10 treatment sessions. Each session lasts approximately 60 minutes. No weekly support call will be provided.~The sessions will take place by videoconference. Main components of the treatment: Motivation for change, Psychoeducation, Behavioral activation, Exposure, Mindfulness and compassion strategies, integration of loss, restoration and reconstruction of meaning, Cognitive reappraisal and Relapse prevention.
Study: NCT06324591

Intervention type: OTHER
Group type: OTHER
Intervention: Collection biological sample and analysis
Description: collection of a stool sample collected at clinical practice check-ups during the first year after diagnosis of Crohn's disease. This is followed by the evaluation of clinical, laboratory and instrumental data at the time of diagnosis
Study: NCT05124548

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep diagnostics
Description: On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep diagnostics
Description: On study day 4, all participants perform a single night sleep assessment in a sleep lab via Polysomnography (PSG) and WHOOP strap, a digital Fitness and health Coach.
Study: NCT06076590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance fluid
Description: Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: maintenance fluid
Description: Patients are randomized to receive ether Multiple electrolytes injection II or Normal Saline for maintenance fluid during the 72 hours after enrollment. Resuscitation fluids and fluids used for drug delivery are not limited.
Study: NCT06061614

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: NGGT002

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT002
Description: NGGT002
Study: NCT05184439

Intervention type: PROCEDURE
Intervention: Adductor magnus tenodesis for recurrent patellar dislocation
Description: In all 33 patients (39 knees) adductor magnus tenodesis was performed to stabilise the patella. Adductor magnus tendon was harvested, cut proximally and fixed to the patella with proper tension.
Study: NCT05306288

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects enrolled in DELFI-L201 will have blood specimens collected (\~30 mL) at enrollment or up to 30 days from enrollment.
Study: NCT05907421

Intervention type: BEHAVIORAL
Intervention: Acceptance mindset
Description: Brief training of acceptance versus emotional reactivity as emotion regulation strategy.

Intervention type: BEHAVIORAL
Intervention: Acceptance mindset
Description: Brief training of acceptance versus emotional reactivity as emotion regulation strategy.
Study: NCT05035420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowmet
Description: Flowmet will be used for a measurement of arterial blood flow within the finger or toe. Flowmet outputs a PPG waveform that will be compared with the NIRS biosensor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: a. Each subject will be monitored with the multimodal system for 10 minutes while sitting quiescent on a chair in resting position. All screening index parameters will be collected and recorded. b. Each subject will be studied for approximately 60-80 minutes while being exposed to a mild Hypercapnia (5% CO2), paced breathing and breath holding followed by a 10-minute recovery time after each task.
Study: NCT05145465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: All the subjects in the telerehabilitation group will measure their heart rate and SpO2 with a pulse oximeter and blood pressure with digital sphygmomanometer themselves before ,during and after the end of each session for safety after they had been taught by physiotherapist. The patients will also oversee their blood sugar level before and after each session in order to prevent hypoglucemia events.~The target heart rate for each patient will set at 60-80% of heart rate reserve plus the heart rate rest and wiil be calculated by the physiotherapist for each patient based on if they receive beta blockers medication or not.
Study: NCT06023290

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Heart rhythm measurements with Preventicus®
Description: The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Heart rhythm measurements with FibriCheck®
Description: The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Heart rhythm measurements with Apple Watch®
Description: The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Heart rhythm measurements with 6L Kardia Mobile®
Description: The sequence of the digital heart rhythm measurements is randomly assigned for each patient. The reference heart rhythm is determined by a simultaneous recording with a 12-lead ECG as gold standard.
Study: NCT05731596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20 Mg Oral Tablet
Description: Rosuvastatin 20 mg will be administered orally once daily for 3 Months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 MG Oral Capsule
Description: Coenzyme Q10 100 mg will be administered orally once daily for 3 Months
Study: NCT06322381

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reinsertion achilles tendon
Description: Prone position, tourniquet over the thigh, direct midline incision, 2.0 cm proximal the insertion of the Achilles tendon up to 4.0 cm prolonged distal to the insertion is recommended. This is followed by a totally disinsertion of TA. At least a debridement of inflammatory or necrotic tissue as well as the removal of bony tissue is performed. tendon is re-inserted by 2-4 anchors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Zadek osteotomy
Description: lateral position, under spinal anesthesia, tourniquet over the thigh, oblique lateral heel incision starting just anterior to the Achilles tendon, at a 45 angle to the long axis of the calcaneus posterior to the course of the sural nerve. A calcaneal osteotomy was then performed, two Kirschner wires, were then inserted from the posterior aspect of the calcaneus, over which cannulated screws were used for fixation of the osteotomy.
Study: NCT05192187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-sectional self-report (questionnaires)
Description: participants in this group will be ask to complete questionnaires on one occasion (i.e., cross-sectional investigation). The questionnaires will consist of a self-developed questionnaire and standard questionnaires. The main aspects of the self-developed questionnaires are~* perceived harmfulness of activities (selection of PHODA-SeV)~* cognitions about lifting and pain~* reasons for avoidance behaviour (lifting)~Standardised questionnaires include~* NRS for pain~* TSK-11~* FABQ~* RMDQ
Study: NCT05162222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicamtiv
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Specified dose on specified days
Study: NCT05963035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PFPN
Description: For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
Study: NCT05150691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV
Study: NCT05934188

Intervention type: BEHAVIORAL
Intervention: Eating habits
Description: Information on eating habits will be derived from food questionnaires.

Intervention type: BEHAVIORAL
Intervention: Eating habits
Description: Information on eating habits will be derived from food questionnaires.
Study: NCT05150691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DB-1303/BNT323
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Administered oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered oral
Study: NCT05076422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05806242

Intervention type: OTHER
Intervention: Italian Validation of the Italian Elderly Mobility Scale (EMS-I)
Description: Two physiotherapists independently evaluate the same enrolled patient with the Italian Elderly Mobility Scale (EMS-I) and Barthel Index
Study: NCT04314687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: The umbilical cord was removed from the donor and brought to cell culture facility immediately. Upon arrival, pre-sterility sample testing was performed to ensure the sample was free from contaminant. Culture processes were conducted in a laboratory room where high sterility and safety were guaranteed. Every batch of the cells was monitored by a series of quality control testing to assure the quality of the product.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium
Description: Conditioned medium collected from umbilical cord mesenchymal stem cell (UC-MSC) cultured. Every batch of the conditioned medium was monitored by a series of quality control testing to assure the quality of the product.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy for cerebral palsy such as physiotherapy
Study: NCT06176703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application
Description: using mobile application along with standard treatment of diabetes mellitus